The Globe and Mail reports in its Thursday, Jan. 15, edition that Stifel analyst Justin Keywood has reaffirmed his "buy" recommendation for Savaria. The Globe's David Leeder writes in the Eye On Equities column that Mr. Keywood boosted his share target by $2 to $28, matching the consensus. Mr. Keywood says in a note: "We raise our SIS target price $2 to $28.00, demonstrating conviction in the assisted lift solutions provider with an expected return to organic growth (4 to 6 per cent), boosted FCF growth (up 15 per cent) as onetime consultant fees drop off and a balance sheet to support M&A (1.2 times levered). New elevator products (Luma), price increases (2-4 per cent) and a Europe leadership change to drive organic growth. M&A funnel remains robust with dealer assets and product opportunities, conservatively factored into forecasts. Savaria sells 10- to 15-per-cent direct with a 30-per-cent target to help further lift already healthy, 20-per-cent EBITDA margins. Age at home is no longer just a demographic preference as a favourable policy backdrop, including subsidies/tax breaks supports lower cost senior care vs. nursing home settings. Q1-Q4 organic growth with robust FCF to drive valuation."